HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors and viruses,
today announced that Walter Klemp,
President and Chief Executive Officer of Moleculin, will present at
the Q2 Virtual Investor Summit on Monday,
May 17th at 12:30 PM
ET.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference. For more information about the conference, please visit
the conference website.
A live video webcast will be accessible on the Events page in
the Investors section of the Company's website (www.moleculin.com)
and archived for 90 days following the event.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors and
viruses. The Company's clinical stage drugs are: Annamycin, a
next-generation anthracycline, designed to avoid multidrug
resistance mechanisms with little to no cardiotoxicity being
studied for the treatment of relapsed or refractory acute myeloid
leukemia, more commonly referred to as AML, WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic cancer
and hematologic malignancies, and WP1220, an analog to WP1066, for
the topical treatment of cutaneous T-cell lymphoma. Moleculin is
also engaged in preclinical development of additional drug
candidates, including other Immune/Transcription Modulators, as
well as WP1122 and related compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-biotech-to-present-at-the-q2-virtual-investor-summit-301288084.html
SOURCE Moleculin Biotech, Inc.